The Centers for Medicare & Medicaid Services (CMS) is considering eliminating a special payment pathway for breakthrough medical devices, according to sources familiar with ongoing policy discussions. The potential change could significantly impact how innovative technologies reach Medicare patients.
Established in 2020, the breakthrough device pathway was designed to accelerate patient access to cutting-edge medical technologies that address unmet clinical needs. Under current rules, manufacturers can secure temporary Medicare coverage while gathering additional evidence of clinical effectiveness.
Analysts suggest the reconsideration stems from concerns about the program’s cost-effectiveness. ‘There’s growing scrutiny about whether these devices demonstrate sufficient value to justify premium reimbursement,’ said one healthcare policy expert who requested anonymity due to ongoing negotiations.
The medical device industry has expressed strong opposition to potential changes. Industry groups argue the pathway is critical for fostering innovation and bringing life-saving technologies to market faster. Patient advocacy organizations are divided, with some emphasizing access to novel treatments while others prioritize evidence-based coverage decisions.
If implemented, the policy shift could take effect as early as 2027, though congressional pushback might delay or modify any proposed changes. The decision comes as CMS faces increasing pressure to balance innovation with fiscal responsibility in the Medicare program.